| Title | [B-lymphocyte depleting and other biological treatment options for Graves' ophthalmopathy] |
| Author(s) | El Fassi D, Nielsen CH, Hegedüs L |
| Institution | Odense Universitetshospital, Endokrinologisk Afdeling M. fassi@dadlnet.dk |
| Source | Ugeskr Laeger 2008 Jun 9; 170(24):2128-30. |
| Abstract | The current medical treatment options for Graves' ophthalmopathy (GO) are unsatisfactory. Recent treatment of GO patients with the B-lymphocyte depleting monoclonal antibody rituximab or with the anti-tumor necrosis factor-alpha agents etanercept and infliximab has shown promising results. We discuss the use of these and other biological agents targeting B lymphocytes, T-lymphocyte interaction with antigen-presenting cells, or cytokines in the future treatment of GO. |
| Language | dan |
| Pub Type(s) | English Abstract
Journal Article
|
| PubMed ID | 18565294 |
